US Pharma MarketingThe post Enrolment concludes in 4Moving Biotech’s Phase IIa trial of 4P004 appeared first on Clinical Trials Arena.
Enrolment concludes in 4Moving Biotech’s Phase IIa trial of 4P004
4Moving Biotech has completed patient enrolment in its Phase IIa INFLAM MOTION trial of 4P004, an intra-articular GLP-1 receptor agonist, for knee osteoarthritis linked to synovitis. The post Enrolment concludes in 4Moving Biotech’s Phase IIa trial of 4P004 appeared first on Clinical Trials Arena .
4Moving Biotech has completed patient enrolment in its Phase IIa INFLAM MOTION trial of 4P004, an intra-articular GLP-1 receptor agonist, for knee osteoarthritis linked to synovitis.
Source: Clinical Trials Arena